Hangzhou Tigermed Consulting (03347) expects the net profit attributable to mother in 2025 to be approximately 830 million to 1.23 billion yuan, a year-on-year increase of 105% to 204%.

Hangzhou Tigermed Consulting (03347) announced that the group is expected to achieve an operating income of 6.66 billion to 7.68 billion yuan by 2025, an increase of 1% to 16% year-on-year; the net profit attributable to shareholders of the listed company is expected to be 830 million to 1.23 billion yuan, an increase of 105% to 204% year-on-year; the net profit after deducting non-recurring gains and losses attributable to shareholders of the listed company is approximately 330 million to 490 million yuan, a decrease of 61% to 43% year-on-year. The announcement stated that the net profit attributable to shareholders of the listed company during the reporting period increased by 105%204% compared to the same period last year, mainly due to a significant increase in non-recurring gains and losses during the reporting period. During the reporting period, the non-recurring gains and losses attributable to shareholders of the listed company amounted to 500 million to 740 million yuan; the non-recurring gains and losses attributable to shareholders of the listed company in the same period last year were approximately -450 million yuan, resulting in an increase of 950 million to 1.19 billion yuan in non-recurring gains and losses. Through relentless efforts, the company's new signed orders in terms of quantity and amount both achieved good growth compared to the same period last year. In 2025, the net addition of orders (new signed orders excluding canceled orders) is expected to be between 9.5 billion to 10.5 billion yuan, while in the same period in 2024, the net addition of orders was 8.42 billion yuan.